These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15544510)

  • 1. Fluoroquinolones as chemotherapeutics against mycobacterial infections.
    Jacobs MR
    Curr Pharm Des; 2004; 10(26):3213-20. PubMed ID: 15544510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of quinolones against mycobacteria.
    Jacobs MR
    Drugs; 1999; 58 Suppl 2():19-22. PubMed ID: 10553700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.
    Locher CP; Jones SM; Hanzelka BL; Perola E; Shoen CM; Cynamon MH; Ngwane AH; Wiid IJ; van Helden PD; Betoudji F; Nuermberger EL; Thomson JA
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1455-65. PubMed ID: 25534737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of quinolones against mycobacteria.
    Jacobs MR
    Drugs; 1995; 49 Suppl 2():67-75. PubMed ID: 8549419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
    Alangaden GJ; Lerner SA
    Clin Infect Dis; 1997 Nov; 25(5):1213-21. PubMed ID: 9402384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.
    Ramaswamy S; Musser JM
    Tuber Lung Dis; 1998; 79(1):3-29. PubMed ID: 10645439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
    Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y
    J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolones: Blessings Or Curses.
    Majalekar PP; Shirote PJ
    Curr Drug Targets; 2020; 21(13):1354-1370. PubMed ID: 32564750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS].
    Pulido F; Iribarren JA; Kindelan JM; Moreno S
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():20-8. PubMed ID: 9859616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
    Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
    Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolones in intracellular infections.
    Pechère JC
    Drugs; 1993; 45 Suppl 3():29-36. PubMed ID: 7689448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
    Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
    Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.